zinostatin and Prostatic-Neoplasms

Prostate cancer patients were treated with a basic therapy of intra-arterial injection of neocarzinostatin (NCS). This therapy was divided into three types of regimen: NCS intra-arterial injection alone, NCS intra-arterial injection + diethylstilbestrol (DES), and NCS intra-arterial injection + aclacinomycin A (ACR) + peplomycin (PEP). A comparative study was carried out on the clinical efficacies of these three regimens, and at the same time an investigation was made of the prognosis in the cases receiving NCS intra-arterial injection alone and NCS + DES. The clinical efficacy was found to be high in each of the three treatment groups in terms of subjective symptoms and laboratory findings, except for ALP. In the evaluation of efficacy on the basis of histological findings, the rates were 60.0% for NCS intra-arterial injection alone, 71.4% for NCS + DES, and 88.2% for NCS + ACR + PEP. Thus, all three of these treatment regimens gave good efficacy rates, but it is especially noteworthy that the combined chemotherapy regimen yielded the highest efficacy rate. On the other hand, the incidence of adverse reactions was much higher in the case of the combined chemotherapy regimen than in the other two regimens. In the patient group administered the NCS intra-arterial injection alone, the one-year survival rate was 75.0% and the 4-year survival rate was 25.0%, while in the NCS + DES treatment group the one-year survival rate was 87.5% and the 4-year survival rate was 37.5%. For individual patients, the correlation between the clinical efficacy and the prognosis was not strong. However, it was concluded that all three of the chemotherapy regimens are useful as forms of remission induction therapy.

Topics: Aclarubicin; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Diethylstilbestrol; Humans; Injections, Intra-Arterial; Male; Middle Aged; Naphthacenes; Peplomycin; Prognosis; Prostatic Neoplasms; Zinostatin

Neocarzinostatin (NCZ), a new antitumor antibiotic, was administered to 19 patients with bladder cancer, 16 patients with prostatic cancer, and 3 patients with hepatoma. All patients had objectively measurable metastatic lesions including 21 with palpable nodes or subcutaneous nodules, 10 with pulmonary nodules as demonstrated by chest x-ray, 4 with malignant hepatomegaly, and 3 with bidimensional pelvic masses as demonstrated by CT scanning. Sixty-five courses of NCZ were administered via an intravenous bolus daily for five days with dosages ranging from 1500 to 3000 U/m2. Immediate toxicity was not dose-limiting except for 1 episode of anaphylaxis and 1 of acute renal failure. Myelotoxicity was delayed, dose-dependent, noncumulative, and dose-limiting. Thrombocytopenia was prolonged or irreversible in 5 cases. The maximally tolerated dose was 2750 U/m2. One patient with NCZ-associated pulmonary fibrosis and 1 with biopsy-proven hepatitis are discussed in detail. Neocarzinostatin demonstrated minimal therapeutic activity (1 partial remission) in patients with bladder cancer. There was no response in patients with prostatic cancer or hepatoma.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Administration Schedule; Drug Evaluation; Female; Hematoma; Humans; Leukopenia; Liver; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Respiratory Function Tests; Thrombocytopenia; Urinary Bladder Neoplasms; Zinostatin